CRISPR Therapeutics (CRSP): ARK's Stock Stories
ARK Invest · 2:47
CRISPR Therapeutics' Casgevy is the first commercially approved CRISPR-edited medicine and a functional one-time cure for sickle cell disease, but commercial uptake is still minuscule — 64 infusions and $116M in reven...